Cencora (COR) DIvidends Date & History

Key Takeaways

• Cencora (COR) pays a quarterly dividend of $0.60 per share, or $2.40 per share annually, for a dividend yield of roughly 0.8%.
• The payout ratio is low at about 18% of earnings and roughly 11% of free cash flow, leaving substantial room for future dividend increases.
• Cencora has raised its dividend for more than 15 consecutive years, with a five-year average annual growth rate near 5.8%.
• The most recent increase, announced in November 2025, lifted the quarterly payout from $0.55 to $0.60 per share, a year-over-year rise of about 9%.
• The modest yield reflects the company's prioritization of dividend growth and share repurchases over maximizing current income.

Dividend Overview

Cencora, Inc. (COR) is a leading pharmaceutical distributor formerly known as AmerisourceBergen. The company pays a quarterly cash dividend of $0.60 per share, equivalent to an annualized payout of $2.40 per share. Based on recent trading levels, this translates to a dividend yield of roughly 0.8%, which is below the broader market average but consistent with many large-capitalization healthcare names.

Cencora is best characterized as a dividend growth stock rather than a high-yield stock. Its yield is modest, but the company has demonstrated a long-term commitment to steadily increasing its payout. The dividend is paid four times per year, and the company has historically complemented its dividend with an active share buyback program, which together lift total shareholder returns.

Dividend History and Growth

Cencora has a well-established record of returning capital to shareholders. The company has increased its dividend for more than 15 consecutive years, and several data providers track a growth streak spanning roughly two decades, with payments stretching back to the early 2000s. Over the past five years, the dividend has grown at an average annual rate of approximately 5.8%.

The company has consistently delivered annual increases rather than large one-time jumps. For example, the quarterly dividend rose from $0.485 per share in 2023 to $0.51 in 2024, then to $0.55 in 2025. The most recent increase, declared in November 2025, brought the quarterly payment to $0.60 per share, a roughly 9% year-over-year advance. This steady, incremental approach reflects a disciplined long-term dividend strategy tied to earnings growth.

Dividend Sustainability and Payout Ratio

Cencora's dividend appears highly sustainable by standard measures. The company's payout ratio (the share of earnings distributed as dividends) is approximately 18%, and the dividend consumes only about 11% of operating cash flow. These figures are well below levels that would raise concern and indicate that the dividend is comfortably covered by both earnings and cash generation.

As a pharmaceutical distributor, Cencora operates a high-volume, lower-margin business that tends to generate predictable cash flow through economic cycles. This stability supports consistent dividend payments. The low payout ratio also gives management significant flexibility to continue raising the dividend over time while reinvesting in the business and maintaining a disciplined balance sheet. The combination of steady cash flow and a conservative payout provides a strong foundation for continued dividend growth.

Dividend Compared to Industry Peers

Cencora operates alongside two primary peers in pharmaceutical distribution: McKesson (MCK) and Cardinal Health (CAH). Within this group, Cencora's dividend yield of roughly 0.8% sits between its competitors. McKesson typically offers a lower yield of around 0.5% to 0.6%, while Cardinal Health generally offers a higher yield of roughly 2%.

Compared with the healthcare sector broadly, which often averages yields in the 1.5% to 2.7% range, Cencora's payout is on the lower end. However, the company compensates for its modest yield with a long history of consistent dividend increases and a very conservative payout ratio. For investors, this means Cencora's dividend profile emphasizes reliability and gradual growth rather than immediate income.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. Explore the AI Screener to refine your search for dividend-paying companies that match your investment criteria.

Is This Stock Attractive for Dividend Investors?

Cencora is likely to appeal primarily to dividend growth investors and long-term, conservative investors rather than those seeking high current income. With a yield below 1%, the stock does not generate significant near-term cash flow for income-focused portfolios. Instead, its appeal lies in its track record of more than 15 consecutive years of dividend increases, a low payout ratio, and predictable cash generation.

Investors who prioritize steadily compounding income over time may find Cencora's profile attractive, particularly when combined with its share repurchase activity. However, those requiring a higher starting yield or substantial dividend income may find better alternatives elsewhere, including direct peers such as Cardinal Health. As with any equity investment, the dividend's long-term growth depends on continued earnings expansion and management's capital-allocation priorities, which can change over time. A balanced view suggests Cencora suits investors focused on modest but dependable dividend growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations